News | May 04, 2026
Bristol Myers Squibb begins 2026 with growth momentum
The company’s Growth Portfolio delivered $6.2 billion in revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
The transaction marks a clear portfolio reshuffle for Indoco
The company posted revenue of Rs. 703 crore in Q4 FY26
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Subscribe To Our Newsletter & Stay Updated
